Table 1

Patient demographics and baseline characteristics

ParameterAnalysis population (N=90)
Age (years), mean (SD)40.8 (11.4)
Female, n (%)76 (84.4)
Race/ethnicity, n (%)
 Black African ancestry13 (14.4)
 Asian3 (3.3)
 Caucasian55 (61.1)
 Hispanic16 (17.8)
 Native American3 (3.3)
Time since SLE diagnosis (years), n (%)
 <1 0 (0)
 1–557 (63.3)
 6–1022 (24.4)
 >1011 (12.2)
Physician-reported SLE disease severity at baseline, n (%)
 Mild1 (1.1)
 Moderate72 (80.0)
 Severe17 (18.9)
SELENA-SLEDAI score at baseline, mean (SD)13.1 (3.0)
SLE-related medication use at baseline, n (%)
 Antimalarials72 (80.0)
 Immunosuppressants43 (47.8)
 Intravenous glucocorticoids4 (4.4)
 Oral glucocorticoids79 (87.8)
Prednisone-equivalent dose (mg/day), mean (SD)*24.8 (15.5)
Presence of SLE organ system manifestation by group, n (%)
 Cardiopulmonary16 (17.8)
 Central nervous system15 (16.7)
 Renal17 (18.9)
 Constitutional50 (55.6)
 Immunological63 (70.0)
 Mucocutaneous62 (68.9)
 Musculoskeletal61 (67.8)
 Vasculitis7 (7.8)
 Haematological48 (53.3)
  • *Among the 79 patients receiving oral glucocorticoids at baseline.

  • SELENA-SLEDAI, Safety of Estrogens in Lupus Erythematosus National Assessment–SLE Disease Activity Index.